157026-18-1

Basic information

• Product Name: 2-Amino-5-Bromo-3-Nitrobenzotrifluoride
• Synonyms: 2-Amino-5-Bromo-3-Nitrobenzotrifluoride;4-Bromo-2-nitro-6-(trifluoromethyl)aniline;4-Bromo-2-nitro-6-(trifluoromethyl)aniline, 2-Amino-5-bromo-3-(trifluoromethyl)nitrobenzene;4-bromo-2-nitro-6-(trifluoromethyl)Benzenamine
• CAS NO: 157026-18-1
• Molecular Formula: C₇H₄BrF₃N₂O₂
• Molecular Weight: 285.03
• Product Categories: Trifluoromethylbenzene serise
• Mol File: 157026-18-1.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 273.474 °C at 760 mmHg
• Flash Point: 119.193 °C
• Appearance: /Solid
• Density: 1.859 g/cm³
• Vapor Pressure: 0.006mmHg at 25°C
• Refractive Index: 1.562
• Storage Temp.: Hygroscopic, Refrigerator, under inert atmosphere
• Solubility: Chloroform (Slightly), Methanol (Slightly)
• PKA: -3.75±0.25(Predicted)
• CAS DataBase Reference: 2-Amino-5-Bromo-3-Nitrobenzotrifluoride(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Amino-5-Bromo-3-Nitrobenzotrifluoride(157026-18-1)
• EPA Substance Registry System: 2-Amino-5-Bromo-3-Nitrobenzotrifluoride(157026-18-1)

Safety Data

• Hazardous Substances Data: 157026-18-1(Hazardous Substances Data)

Usage

Uses

4-Bromo-2-nitro-6-(trifluoromethyl)aniline is a reagent for the preparation of 3-(5-arylbenzimidazol-2-yl)-1-oxa-2-azaspiro[4.5]decenes, a transient receptor potential melastatin 8 (TRPM8) antagonist for the treatment of painful conditions related to cold.

InChI:InChI=1/C7H4BrF3N2O2/c8-3-1-4(7(9,10)11)6(12)5(2-3)13(14)15/h1-2H,12H2

Upstream product

• 24821-17-8 2-Nitro-6-(trifluoromethyl)aniline 
• 1155800-52-4 N-(4-bromo-2-nitro-6-(trifluoromethyl)phenyl)-2,2,2-trifluoroacetamide 
• 105172-74-5 3-bromo-5-nitro-6-chlorobenzotrifluoride 
• 29124-62-7 N-(4-bromo-2-trifluoromethyl-phenyl)-acetamide 
• 445-02-3 4-bromo-2-trifluoromethyl-aniline 
• 179062-00-1 N-(4-bromo-2-nitro-6-trifluoromethyl-phenyl)-acetamide 

Downstream Products

• 157026-19-2 5-bromo-3-(trifluoromethyl)-1,2-benzenediamine 
• 1326310-54-6 4-cyclopropyl-2-nitro-6-(trifluoromethyl)aniline 
• 1326310-55-7 5-cyclopropyl-3-(trifluoromethyl)-1,2-benzenediamine 
• 1221349-87-6 1-oxa-2-aza-spiro[4.5]dec-2-ene-3-carboxylic acid (4-amino-5,2'-bis-trifluoromethyl-biphenyl-3-yl)-amide 
• 1276115-85-5 C₂₃H₂₁F₆N₃O₂ 
• 1276127-36-6 C₂₂H₂₁ClF₃N₃O₂ 
• 1276127-37-7 C₂₂H₂₁ClF₃N₃O₂ 
• 1276127-34-4 C₂₃H₂₁F₆N₃O₃ 
• 1276127-35-5 C₂₃H₂₁F₆N₃O₃ 
• 1276127-20-8 C₂₂H₂₁F₄N₃O₂ 
• 1276127-33-3 C₂₂H₂₁F₄N₃O₂ 
• 1259026-14-6 JNJ-41876666 
• 1221349-53-6 3-[7-trifluoromethyl-5-(2-trifluoromethylphenyl)-1H-benzimidazol-2-yl]-1-oxa-2-azaspiro[4.5]dec-2-ene 
• 1221349-68-3 3-[7-trifluoromethyl-5-(2-trifluoromethylphenyl)-1H-benzimidazol-2-yl]-1,8-dioxa-2-azaspiro[4.5]dec-2-ene 

Relevant articles and documents

BENZIMIDAZOLE ANTIVIRAL AGENTS

Provided are compounds of Formula (I) and (II) and pharmaceutically acceptable salts thereof, their pharmaceutical compositions, their methods of preparation, and their use for treating viral infections mediated by a member of the Flaviviridae family of viruses such as hepatitis C virus (HCV).

An efficient synthetic process for scale-up production of 4,5-diamino-2- (trifluoromethyl)benzonitrile and 5-bromo-3-(trifluoromethyl)benzene-1,2-diamine

Starting from 4-amino-2-(trifluoromethyl)benzonitrile (6), an efficient and nonchromatographic process was developed for multihundred gram production of 4,5-diamino-2-(trifluoromethyl)- benzonitrile (1) in 73% yield and 98 HPLC area% purity over four synthetic steps. The same synthetic strategy was applied to 4-bromo-2-(trifluoromethyl)aniline (7) that afforded 5-bromo-3- (trifluoromethyl)benzene-1,2-diamine (5) in 81% overall yield and 99% HPLC area% purity.

Glycine receptor antagonists and the use thereof

Methods of treating or preventing neuronal loss associated with stroke, ischemia, CNS trauma, hypoglycemia and surgery, as well as treating neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease and Down's syndrome, treating or preventing the adverse consequences of the hyperactivity of the excitatory amino acids, as well as treating anxiety, chronic pain, convulsions, inducing anesthesia and treating psychosis are disclosed by administering to an animal in need of such treatment a compound having high affinity for the glycine binding site, lacking PCP side effects and which crosses the blood brain barrier of the animal. Also disclosed are novel 1,4-dihydroquinoxaline-2,3-diones, and pharmaceutical compositions thereof. Also disclosed are highly soluble ammonium salts of 1,4-dihydroquinoxaline-2,3-diones.